ImmunoScape Announces Three Presentations Highlighting TCR Pipeline and Discovery Platform at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-20
免疫疗法AACR会议临床研究细胞疗法
SAN DIEGO & SINGAPORE--(BUSINESS WIRE)-- ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, California.
Presentation details are as follows:
Title: Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumors
Presenter: Juliana Velez Lujan, Ph.D., ImmunoScape, Senior Scientist
Session Title: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 1
Poster Number: 13
Title: Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptors
Presenter: Hannah Fields, ImmunoScape, Scientist
Session Title: Adoptive Cell Therapies 1: Tumor Antigen Specific T-cells and TCR-T
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 1
Poster Number: 8
Title: A validated bioinformatics tool-set for predicting TCR specificity
Presenter: Andreas Wilm, ImmunoScape, Director of Computational Biology
Session Title: Database Resources, Statistical Methods, and Other Tools
Date & Time: Monday, April 8, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 36
Poster Number: 19
Full abstracts will be available on the AACR Online Program Planner. Following the conference, the posters will be made available under the “Publications” page on ImmunoScape's website.
About ImmunoScape
ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit .
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。